MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
The mPTP plays a key role in mitochondrial dysfunction, inflammation, and neuronal death in neurodegenerative diseases
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
Subscribe To Our Newsletter & Stay Updated
